DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MITOXANTRONE HYDROCHLORIDE

« Back to Dashboard

All Clinical Trials for Mitoxantrone Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002003	Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas	Completed	Lederle Laboratories	Phase 2	1969-12-31	To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
NCT00002259	Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma	Completed	Lederle Laboratories	Phase 2	1969-12-31	To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
NCT00002474	Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer	Completed	Loyola University	Phase 2	1991-02-01	RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.
NCT00002498	Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer	Unknown status	Leiden University Medical Center	Phase 2	1992-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of cyclophosphamide, methotrexate, and fluorouracil with mitoxantrone in treating older patients with recurrent or metastatic breast cancer.
NCT00002514	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Medical Research Council	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	National Cancer Institute (NCI)	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Eastern Cooperative Oncology Group	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.

Clinical Trial Conditions for Mitoxantrone Hydrochloride

Condition Name

Condition Name for Mitoxantrone Hydrochloride
Intervention	Trials
Leukemia	49
Acute Myeloid Leukemia	40
Prostate Cancer	28
Lymphoma	25

Condition MeSH

Condition MeSH for Mitoxantrone Hydrochloride
Intervention	Trials
Leukemia	167
Leukemia, Myeloid, Acute	123
Leukemia, Myeloid	123
Lymphoma	61

Clinical Trial Locations for Mitoxantrone Hydrochloride

Trials by Country

Trials by Country for Mitoxantrone Hydrochloride
Location	Trials
United States	935
Canada	102
Germany	51
Spain	47
France	46

Trials by US State

Trials by US State for Mitoxantrone Hydrochloride
Location	Trials
California	49
New York	46
Ohio	41
Illinois	39
Washington	38

Clinical Trial Progress for Mitoxantrone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Mitoxantrone Hydrochloride
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	81
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for Mitoxantrone Hydrochloride
Clinical Trial Phase	Trials
Completed	143
Recruiting	64
Terminated	34

Clinical Trial Sponsors for Mitoxantrone Hydrochloride

Sponsor Name

Sponsor Name for Mitoxantrone Hydrochloride
Sponsor	Trials
National Cancer Institute (NCI)	74
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	16
Fred Hutchinson Cancer Research Center	11

Sponsor Type

Sponsor Type for Mitoxantrone Hydrochloride
Sponsor	Trials
Other	327
Industry	130
NIH	75